Active Tuberculosis Treatment

Aka: Active Tuberculosis Treatment, Active Tuberculosis, Active Tb Treatment, Active Tb, Active Tuberculosis Special Circumstances, Drug-Induced Hepatitis from Antituberculous Drugs

advertisement

II. Diagnosis

  1. See Tuberculosis
  2. Requires idenitifying Acid Fast Bacteria
  3. Tuberculosis Screening (TST, IGRA) is insufficient to diagnose Active Tb

III. Precautions

  1. Tuberculosis requires long-term treatment
    1. Requires at least 4 months of medications (extended as long as 24 months in some cases)
  2. Regimens for Tuberculosis treatment must be multi-drug
    1. Four drugs should be used initially until culture (returned by 6-8)
    2. Never add a single drug to a failing regimen
    3. Avoid the Susceptible Tb Treatment protocol in suspected resistant Tuberculosis
      1. See Possibly Resistant Tb Treatment
      2. See Multiple Drug Resistant Tb Treatment
  3. Patients must be monitored at least monthly
  4. Patient noncompliance is a major problem
    1. Consider intermittent therapy
    2. Consider Directly observed therapy
  5. Patients must be isolated (quarantined) until non-infectious
    1. Patient should stay in their home and wear a mask around others (or negative airflow room in facility)
    2. Non-infectious status is confirmed with three induced Sputum samples negative for acid-fast Bacteria
    3. Patients become non-infectious at 2-4 weeks after initiating Antibiotics

IV. Drug Interactions

  1. Review Drug Interactions before use (esp. Rifampin)

V. Adverse Effects: Tuberculosis Medications

  1. Gastrointestinal upset
    1. Consider taking medication with food
    2. Consider Antacid use
  2. Hepatotoxin (AST 3-5x normal)
    1. See Also Hepatotoxin
    2. Consider alternatives below if advanced liver disease
    3. Drugs most likely to cause Drug-Induced Hepatitis
      1. Isoniazid
      2. Rifampin (less with Rifapentine)
      3. Pyrazinamide
    4. Alternative drugs if Drug-Induced Hepatitis occurs
      1. Capreomycin
      2. Fluoroquinolone
      3. Ethambutol
      4. Streptomycin
      5. Amikacin
      6. Kanamycin
  3. Peripheral Neuropathy
    1. Isoniazid (INH)
  4. Optic Neuritis
    1. Ethambutol (EMB)
  5. Gout
    1. Pyrazinamide (PZA)
  6. Ototoxicity
    1. Streptomycin (and other Aminoglycosides)
  7. Renal Toxin
    1. Streptomycin (and other Aminoglycosides)
  8. Discolored body fluids
    1. Rifampin causes red-orange Urine Color, stool color, Saliva, sweat and tears

VI. Labs

  1. Obtain 3 initial Acid-fast bacilli smears and cultures (or DNA testing)
    1. Repeat testing monthly until 2 consecutive tests are negative
  2. Acid-fast bacilli smears, DNA and cultures are critical to management
    1. Determine the drug regimen used
    2. Determine the duration of the continuation phase of treatment

VII. Management: Protocols

  1. Susceptible Tb Treatment
  2. Possibly Resistant Tb Treatment
  3. Multiple Drug Resistant Tb Treatment

VIII. Management: Standard Adult

  1. See Susceptible Tb Treatment
  2. Background
    1. Four Drug Therapy with Moxifloxacin and Rifapentine 4 Month Course (2022 Regimen)
    2. This protocol assumes susceptible Tuberculosis
      1. See Susceptible Tb Treatment for complete description and indications
    3. Avoid this protocol in suspected resistant Tuberculosis
      1. See Possibly Resistant Tb Treatment
      2. See Multiple Drug Resistant Tb Treatment
  3. Indications
    1. Age =12 years AND body weight =40 kg
    2. Pulmonary TB caused by organisms that are not known or suspected to be drug-resistant
  4. Contraindications
    1. Age <12 years or weight <40 kg
      1. Use the Ethambutol/Rifampin protocol for total of 4 months instead (see below)
    2. Pregnancy or Breastfeeding
      1. Requires 24 week course with a different regimen
    3. Extrapulmonary Tuberculosis (esp. CNS involvement)
  5. Phase 1: Intensive for first 8 weeks
    1. Rifapentine (RPT) 1200 mg orally daily
    2. Moxifloxacin (MOX) 400 mg orally daily
    3. Isoniazid (INH) 300 mg orally daily
    4. Pyrazinamide (PZA) 1000, 1500 or 2000 mg (based on weight <55 kg, 55-75 kg, or >75 kg)
  6. Phase 2: Continuation for additional 9 weeks
    1. Rifapentine (RPT) 1200 mg orally daily
    2. Moxifloxacin (MOX) 400 mg orally daily
    3. Isoniazid (INH) 300 mg orally daily
  7. Adjunctive
    1. Vitamin B6 (Pyridoxine) 25-50 mg daily
      1. Indicated for Neuropathy risk due to INH (e.g. Diabetes Mellitus, Alcoholism)
      2. See Isoniazid for details
  8. Monitoring
    1. Liver Function Tests at baseline and 3 months
    2. Renal Function baseline (may affect Pyrazinamide dosing)
  9. References
    1. Carr (2022) MMWR Morb Mortal Wkly Rep 71(8):285-289 +PMID: 35202353 [PubMed]

IX. Management: Special Circumstances

  1. Human Immunodeficiency Virus Infection
    1. Avoid once weekly continuation phase protocols
  2. Pediatric patients
    1. Start empiric treatment immediately if suspected
      1. High risk of Disseminated tuberculosis
    2. Initial Protocol
      1. Three drug regimen indicated in most cases (contrast with adults where 4 drug regimen used)
        1. Regimen: Isoniazid, Pyrazinamide, Rifampin
        2. Ethambutol avoided due to decreased Vision risk
      2. Four drug regimen (inc. Ethambutol) indications
        1. Upper lobe infitrate
        2. Cavitation
        3. Productive cough
  3. Pregnant Women
    1. Initial Regimen: Isoniazid, Rifampin, Ethambutol
    2. Give Pyridoxine 25 mg daily (prevents Neuropathy)
    3. Do not use Streptomycin in pregnancy
    4. Pyrazinamide appears safe in pregnancy
      1. Less studied, and avoided in some regimens
      2. Give 7 month continuation phase if no Pyrazinamide
  4. Lactation
    1. May continue to Breast feed on antituberculous drugs
    2. Give Pyridoxine 25 mg daily (prevents Neuropathy)

X. Management: Non-compliance

  1. General
    1. Compliance management is imperative
    2. Non-compliance causes treatment failures, resistance
  2. Dosing should be observed unless compliance assured
  3. Consider fixed dose combinations
    1. Rifater
      1. Contents
        1. Rifampin 120 mg
        2. Isoniazid 50 mg
        3. Pyrazinamide 300mg
      2. Treat for first 2 months of daily therapy
        1. Weight <44 kg: 4 tabs qd
        2. Weight 45-54 kg: 5 tabs qd
        3. Weight >55 kg: 6 tabs qd
    2. Rifamate
      1. Rifampin 300 mg
      2. Isoniazid 150 mg

XI. Resources

  1. CDC Tb Guidelines Treatment
    1. http://www.cdc.gov/tb/publications/guidelines/treatment.htm

XII. References

  1. (2016) Presc Lett 23(10)
  2. Swadron (2019) Pulmonology 2, CCME Emergency Medicine Board Review, accessed 6/16/2019
  3. Frieden (2003) Lancet 362:887-99 [PubMed]
  4. Nahid (2016) Clin Infect Dis 63(7): e147-95 [PubMed]
  5. Potter (2005) Am Fam Physician 72:2225-35 [PubMed]

Images: Related links to external sites (from Bing)

These images are a random sampling from a Bing search on the term "Active Tuberculosis Treatment." Click on the image (or right click) to open the source website in a new browser window. Search Bing for all related images

Related Studies

Ontology: Active tuberculosis (C0151332)

Concepts Disease or Syndrome (T047)
SnomedCT 427099000
English Active tuberculosis, Active tuberculosis (disorder), active tuberculosis
Spanish tuberculosis activa (trastorno), tuberculosis activa, Tuberculosis activa
Portuguese Tuberculose activa
Italian Tubercolosi attiva
German Aktive Tuberkulose
French Tuberculose active
Dutch actieve tuberculose
Czech Aktivní tuberkulóza
Japanese ｶﾂﾄﾞｳｾｲｹｯｶｸ, 活動性結核
Hungarian Aktív tuberculosis
Derived from the NIH UMLS (Unified Medical Language System)

Related Topics in Tuberculosis

advertisement

2025 Family Practice Notebook, LLC. Terms | Privacy | About | Site Map | Newsletter | Blog

Footer Site Logo